Leerink Partners Maintains Outperform on Definium Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $30 to $52.
Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $30 to $52.